Fecal HMGB1 is a novel marker of intestinal mucosal inflammation in pediatric inflammatory bowel disease

American Journal of Gastroenterology

Volumn 106, Issue 11, 2011, Pages 2029-2040

  Vitali, Roberta ^a   Stronati, Laura ^a   Negroni, Anna ^a   Di Nardo, Giovanni ^b   Pierdomenico, Maria ^a   Del Giudice, Emanuela ^b   Rossi, Paolo ^b   Cucchiara, Salvatore ^b  

^a ENEA   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CALGRANULIN; HIGH MOBILITY GROUP B1 PROTEIN; MESSENGER RNA;

ADOLESCENT; ADULT; ARTICLE; CELL NUCLEUS; CELLULAR DISTRIBUTION; CHILD; CLINICAL ARTICLE; COLONOSCOPY; CONTROLLED STUDY; CROHN DISEASE; CYTOPLASM; ENTERITIS; FECES ANALYSIS; FECES LEVEL; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; INTESTINE BIOPSY; INTESTINE MUCOSA; MALE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; REAL TIME POLYMERASE CHAIN REACTION; SCHOOL CHILD; ULCERATIVE COLITIS; WESTERN BLOTTING;

ACTIVE TRANSPORT, CELL NUCLEUS; ADOLESCENT; BIOLOGICAL MARKERS; BIOPSY; CACO-2 CELLS; CELL NUCLEUS; CHILD; CHILD, PRESCHOOL; COLITIS, ULCERATIVE; CROHN DISEASE; FECES; FEMALE; HMGB1 PROTEIN; HUMANS; INFANT; INTERFERON-ALPHA; INTERFERON-GAMMA; INTERLEUKIN-8; INTESTINAL MUCOSA; MALE; RNA, MESSENGER;

EID: 80655127791     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1038/ajg.2011.231     Document Type: Article

References (42)

1. Srikrishna G, Freeze HH. Endogenous damage-associated molecular pattern molecules at the crossroads of infl ammation and cancer. Neoplasia 2009; 11: 615-28.
2. Bianchi ME. DAMPs, PAMPs and alarmins: all we need to know about danger. J Leuk Biol 2007; 81: 1-5. (Pubitemid 46028489)
3. Seong SY, Matzinger P. Hydrophobicity: an ancient damage-associated molecular pattern that initiates innate immune responses. Nat Rev Immunol. 2004; 4: 469-7.
4. Wang H, Bloom O, Zhang M et al. HMG-1 as a late mediator of endotoxin lethality in mice. Science 1999; 285: 248-51. (Pubitemid 29329996)
5. Th omas JO. HMG1 and 2: architectural DNA-binding proteins. Biochem Soc Trans 2001; 29: 395-401.
6. Yang H, Tracey KJ. Targeting HMGB1 in infl ammation. Biochim Biophys Acta 2010; 1799: 149-56.
7. Bianchi ME, Manfredi AA. High-mobility group box 1 (HMGB1) protein at the crossroads between innate and adaptive immunity. Immunol Rev 2007; 220: 35-46. (Pubitemid 350045574)
8. Ulloa L, Messmer D. High-mobility group box 1 (HMGB1) protein: friend and foe. Cytokine Growth Factor Rev 2006; 17: 189-201. (Pubitemid 43949075)
9. Lotze MT, Tracey KJ. High-mobility group box 1 protein (HMGB1): nuclear weapon in the immune arsenal. Nat Rev Immunol 2005; 5: 331-42. (Pubitemid 40516158)
10. Gardella S, Andrei C, Ferrera era D et al. The nuclear protein HMGB1is secreted by monocytes via a non-classical, vesicle-mediated secretory pathway. EMBO Rep 2002; 3: 995-1001. (Pubitemid 35256475)
11. Yang H, Wang H, Czura CJ et al. HMGB1 as a cytokine and therapeutic target. J Endotoxin Res 2002; 8: 469-72.
12. Scaffi di P, Misteli T, Bianchi ME. Release of chromatin protein HMGB1 by necrotic cells triggers infl ammation. Nature 2002; 418: 191-5. (Pubitemid 34773774)
13. Sims GP, Rowe DC, Rietdijk ST et al. HMGB1 and RAGE in infl ammation and cancer. Annu Rev Immunol 2010; 28: 367-8.
14. Wang H, Yang H, Tracey KJ. Extracellular role of HMGB1 in infl ammation and sepsis. J. Intern Med 2004; 255: 320-31. (Pubitemid 38324549)
15. Andersson U, Harris HE. The role of HMGB1 in the pathogenesis of rheumatic disease. Biochim Biophys Acta 2010; 1799: 141-8.
16. Luki IK, Jelisi-Drazi M, Kovaci N et al. Damage-associated molecular patterns-emerging targets for biologic therapy of childhood arthritides. Infl amm Allergy Drug Targets 2009; 8: 139-45.
17. Pan HF, Wu GC, Li WP et al. High Mobility Group Box 1: a potential therapeutic target for systemic lupus erythematosus. Mol Biol Rep 2010; 37: 1191-5.
18. Zhang S, Zhong J, Yang P et al. HMGB1, an innate alarmin, in the pathogenesis of type 1 diabetes. Int J Clin Exp Pathol 2009; 3: 24-38.
19. Fink MP. Sepsis, ghrelin, the cholinergic anti-infl ammatory pathway, gut mucosal hyperpermeability, and high-mobility group box 1. Crit Care Med 2009; 37: 2483-5.
20. Yang R, Miki K, Oksala N et al. Bile high-mobility group box 1 contributes to gut barrier dysfunction in experimental endotoxemia. Am J Physiol Regul Integr Comp Physiol 2009; 297: R362-9.
21. Liu S, Stolz DR, Sappington PL et al. HMGB1 is secreted by immunostimulated enterocytes and contributes to cytomix-induced hyperpermeability of Caco2 monolayers. Am J Physiol Cell Physiol 2006; 290: C990-9.
22. Sappington PL, Yang R, Yang H et al. HMGB1 B box increases the permeability of Caco-2 enterocytic monolayers and impairs intestinal barrier function in mice. Gastroenterology 2002; 123: 790-802. (Pubitemid 34977085)
23. Dav è SH, Tilstra JS, Matsuoka K et al. Ethyl pyruvate decreases HMGB1 release and ameliorates murine colitis. J Leukoc Biol 2009; 86: 633-43.
24. Maeda S, Hikiba Y, Shibata W et al. Essential roles of high-mobility group box 1 in the development of murine colitis and colitis-associated cancer. Biochem Biophys Res Commun 2007; 360: 394-400. (Pubitemid 47030357)
25. Bousvaros A, Antonioli DA, Colletti RB, et al., North American Society for Pediatric Gastroenterology, Hepatology and Nutrition; Colitis Foundation of America. Diff erentiating ulcerative colitis from Crohn disease in children and young adults: report of a working group of the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition and the Crohn's and Colitis Foundation of America. J Pediatr Gastroenterol Nutr 2007; 44: 653-74.
26. Hyams JS, Mandel F, Ferry GD et al. Development and validation of a pediatric Crohn's disease activity index. J Pediatr Gastroenterol Nutr 1991; 12: 439-47.
27. Turner D, Otley AR, Mack D et al. Development, validation, and evaluation of a pediatric ulcerative colitis activity index: a prospective multicenter study. Gastroenterology 2007; 133: 423-32. (Pubitemid 47193130)
28. Daperno M, D ' Haens G, Van Assche G et al. Development and validation of a new, simplifi ed endoscopic activity score for Crohn's disease: the SES-CD. Gastrointest Endosc 2004; 60: 505-12. (Pubitemid 39311530)
29. Osada T, Ohkusa T, Yokoyama T et al. Comparison of several activity indices for the evaluation of endoscopic activity in UC: inter-and intraobserver consistency. Infl amm Bowel Dis 2010; 16: 192-7.
30. Diamanti A, Panetta F, Basso MS et al. Diagnostic work-up of infl ammatory bowel disease in children: the role of calprotectin assay. Infl amm Bowel Dis 2010; 16: 1926-30.
31. Ito I, Fukazawa J, Yoshida M. Post-translational methylation of high mobility group box 1 (HMGB1) causes its cytoplasmic localization in neutrophils. J Biol Chem 2007; 282: 16336-44. (Pubitemid 47100350)
32. Suda K, Kitagawa Y, Ozawa S et al. Anti-high-mobility group box chromosomal protein 1 antibodies improve survival of rats with sepsis. World J Surg 2006; 30: 1755-62. (Pubitemid 44411235)
33. Abeyama K, Stern DM, Ito Y et al. The N-terminal domain of thrombomodulin sequesters high-mobility group-B1 protein, a novel anti-infl ammatory mechanism. J Clin Invest 2005; 115: 1267-74. (Pubitemid 40629045)
34. Muhammad S, Barakat W, Stoyanov S et al. The HMGB1 receptor RAGE mediates ischemic brain damage. J Neurosci 2008; 28: 12023-31.
35. Tsung A, Sahai R, Tanaka H et al. The nuclear factor HMGB1mediates hepatic injury aft er murine liver ischemia-reperfusion. J Exp Med 2005; 201: 1135-43. (Pubitemid 40524681)
36. Yuan H, Jin X, Sun J et al. Protective eff ect of HMGB1a box on organ injury of acute pancreatitis in mice. Pancreas 2009; 38: 143-8.
37. Ueno H, Matsuda T, Hashimoto S et al. Contributions of high mobility group box protein in experimental and clinical acute lung injury. Am J Respir Crit Care Med 2004 ; 170: 1310-6. (Pubitemid 39657195)
38. Gong Q, Xu JF, Yin H et al. Protective eff ect of antagonist of high mobility group box 1 on lipopolysaccharide-induced acute lung injury in mice. Scand J Immunol 2009; 69: 29-35.
39. Allez M, L é mann M. Role of endoscopy in predicting the disease course in infl ammatory bowel disease. World J Gastroenterol 2010; 16: 2626-32.
40. Bonaldi T, Talamo F, Scaffi di P et al. Monocytic cells hyperacetylate chromatin protein HMGB1 to redirect it towards secretion. EMBO J 2003; 22: 5551-60. (Pubitemid 37279964)
41. Youn JH, Shin JS. Nucleocytoplasmatic shuttling of HMGB1 is regulated by phosphorylation that redirects it toward secretion. J Immunol 2006; 177: 7889-97.
42. Oh YJ, Youn JH, Ji Y et al. HMGB1 is phosphorylated by classical protein kinase C and is secreted by a calcium-dependent mechanism. J Immunol 2009; 182: 5800-9.